行情

BVXV

BVXV

BiondVax
NASDAQ

实时行情|Nasdaq Last Sale

8.90
-0.25
-2.73%
已收盘, 16:00 02/20 EST
开盘
9.05
昨收
9.15
最高
9.11
最低
8.80
成交量
8,598
成交额
--
52周最高
13.50
52周最低
4.650
市值
8,952.32万
市盈率(TTM)
-86.4917
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BVXV 新闻

  • UPDATE: BiondVax Says Prelim. Data Indicates Both Primary Objectives For Phase 2 Trial Met
  • Benzinga.02/05 18:02
  • BoindVax Pharma Reports Prelim. Data From Phase 2 Trial Of M-001 Universal Flu Vaccine Candidate
  • Benzinga.02/05 18:01
  • Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials
  • PR Newswire.02/05 18:00
  • BiondVax Announces Warrant Agreement Amendment to Permit Holders of Warrants to Exercise Both on a Cash and Cashless Basis
  • PR Newswire.01/16 20:05

更多

所属板块

生物技术和医学研究
+0.09%
制药与医学研究
-0.40%

热门股票

名称
价格
涨跌幅

BVXV 简况

BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
展开

Webull提供Biondvax Pharmaceuticals Ltd - ADR的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。